Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Berrettini, W. H. Articles by Lerman, C. E. Search for Related Content PubMed Citation Articles by Berrettini, W. H. Articles by Lerman, C. E. Nicotine Genetics

Pharmacotherapy and Pharmacogenetics of Nicotine Dependence

The authors review recent advances in the pharmacotherapy and pharmacogenetics of nicotine dependence. Despite the negative health consequences of smoking, approximately 23% of adults in the United States are daily tobacco smokers and approximately 13% are nicotine dependent. Data for development of new medications for nicotine dependence are likely to come from animal models of the reinforcing value of nicotine, studies to identify proteins in transgenic rodents, and pharmacological studies of nicotine withdrawal. The initial pharmacogenetic studies of pharmacotherapies approved by the United States Food and Drug Administration for treatment of nicotine dependence—nicotine replacement (nicotine gum, nicotine nasal spray, and transdermal nicotine) and bupropion—have identified candidate alleles at the dopamine D₂ receptor gene and µ opioid receptor gene that may predict therapeutic response. Because no one medication is likely to be safe and efficacious for a majority of persons with nicotine dependence, it will be useful to develop genetics-based methods and other tools to predict therapeutic response in subgroups of nicotine-dependent persons.

This article has been cited by other articles:

				T.-Y. Wu, C. M. Smith, S. M. Sine, and M. M. Levandoski Morantel Allosterically Enhances Channel Gating of Neuronal Nicotinic Acetylcholine {alpha}3{beta}2 Receptors Mol. Pharmacol., August 1, 2008; 74(2): 466 - 475. [Abstract] [Full Text] [PDF]

				M. J. Eisenberg MD MPH, K. B. Filion MSc, D. Yavin BSc, P. Belisle MSc, S. Mottillo BSc, L. Joseph PhD, A. Gervais MD, J. O'Loughlin PhD, G. Paradis MD MSc, S. Rinfret MD MSc, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials Can. Med. Assoc. J., July 15, 2008; 179(2): 135 - 144. [Abstract] [Full Text] [PDF]

				B. A. Johnson New Weapon to Curb Smoking: No More Excuses to Delay Treatment. Arch Intern Med, August 14, 2006; 166(15): 1547 - 1550. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us